Improving access to molecular diagnostics for non-acute settings: New strategic partnership announced
This partnership extends Diasorin’s existing strategic agreements, focusing on supporting long-term growth in decentralized healthcare by integrating their LIAISON NES platform with McKesson’s distribution network.
Diasorin and McKesson Medical Surgical have entered into a strategic distribution agreement to improve accessibility of molecular diagnostics across non-acute settings, according to Diasorin.
The partnership includes leveraging McKesson’s non-acute customer base in the U.S. and Diasorin’s LIAISON NES platform, along with their Flu A/B, RSV & COVID-19 Panel. Physician offices, urgent care centers, and other care centers that provide decentralized testing will gain access to the mentioned molecular diagnostic capabilities.
McKesson will also “support Diasorin’s long-term expansion in decentralized care.” The partnership is an extension of Diasorin’s already established strategic agreements and U.S. commercial organization, according to the company.
